A novel biodegradable polymer-coated sirolimus-eluting stent: 1-year results of the HELIOS registry.
10.1097/CM9.0000000000002324
- Author:
Bo ZHENG
1
;
Yi LIU
1
;
Ruining ZHANG
1
;
Wangwei YANG
1
;
Fangju SU
1
;
Rutao WANG
1
;
Dapeng CHEN
2
;
Guidong SHEN
3
;
Yumin QIU
4
;
Lianmin WANG
5
;
Chang CHEN
6
;
Zhongwei WU
7
;
Fei LI
1
;
Jiayi LI
1
;
Chengxiang LI
1
;
Chao GAO
1
;
Ling TAO
1
Author Information
1. Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China.
2. Internal Medicine of Heart Centre, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003, China.
3. Department of Cardiology, Ankang City Central Hospital, Ankang, Shaanxi 725099, China.
4. Department of Cardiovascular, Cardio-cerebrovascular Hospital affiliated to Ningxia Medical University, Yinchuan, Ningxia 750002, China.
5. Department of Cardiology, Mudanjiang Cardiovascular hospital, Mudanjiang, Harbin 157011, China.
6. Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
7. Department of Cardiology, Western Central Hospital of Hainan Province, Danzhou, Hainan 571700, China.
- Collective Name:HELIOS Investigators
- Publication Type:Journal Article
- MeSH:
Humans;
Middle Aged;
Sirolimus/therapeutic use*;
Drug-Eluting Stents/adverse effects*;
Prospective Studies;
Cohort Studies;
Treatment Outcome;
Risk Factors;
Time Factors;
Percutaneous Coronary Intervention/adverse effects*;
Cardiovascular Agents/therapeutic use*;
Coronary Artery Disease/therapy*;
Myocardial Infarction/etiology*;
Thrombosis/complications*;
Polymers;
Registries
- From:
Chinese Medical Journal
2023;136(15):1848-1854
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:The HELIOS stent is a sirolimus-eluting stent with a biodegradable polymer and titanium oxide film as the tie-layer. The study aimed to evaluate the safety and efficacy of HELIOS stent in a real-world setting.
METHODS:The HELIOS registry is a prospective, multicenter, cohort study conducted at 38 centers across China between November 2018 and December 2019. A total of 3060 consecutive patients were enrolled after application of minimal inclusion and exclusion criteria. The primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, non-fatal target vessel myocardial infarction (MI), and clinically indicated target lesion revascularization (TLR) at 1-year follow-up. Kaplan-Meier methods were used to estimate the cumulative incidence of clinical events and construct survival curves.
RESULTS:A total of 2998 (98.0%) patients completed the 1-year follow-up. The 1-year incidence of TLF was 3.10% (94/2998, 95% closed interval: 2.54-3.78%). The rates of cardiac death, non-fatal target vessel MI and clinically indicated TLR were 2.33% (70/2998), 0.20% (6/2998), and 0.70% (21/2998), respectively. The rate of stent thrombosis was 0.33% (10/2998). Age ≥60 years, diabetes mellitus, family history of coronary artery disease, acute myocardial infarction at admission, and device success were independent predictors of TLF at 1 year.
CONCLUSION:The 1-year incidence rates of TLF and stent thrombosis were 3.10% and 0.33%, respectively, in patients treated with HELIOS stents. Our results provide clinical evidence for interventional cardiologists and policymakers to evaluate HELIOS stent.
CLINICAL TRIAL REGISTRATION:ClinicalTrials.gov, NCT03916432.
